Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies, focusing on the therapeutic areas of oncology, autoimmune diseases and ophthalmic diseases. We keep the momentum for a diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. The two R&D facilities, located in Shanghai and California, are respectively responsible for late-stage development and early-stage development, to ensure the highly productive and cost-efficient R&D processes through close collaboration.
We have established a quality management system that covers the entire product lifecycle in accordance with the quality standards of the US, the EU and China. Xuhui Facility, constructed in 2016 with commercial capacity of 24,000L, is certificated by China and the EU GMP along with the quality management system. Songjiang First Plant, constructed in 2020 with commercial capacity of 24,000L, is certificated by China GMP and the EU QP along with the quality management system.Meanwhile, the construction of Songjiang Second Plant Phase 1 Project is on track. The first and second stages aim to achieve a total capacity of 36,000L. They are expected to enter trial production and relevant verifications in the second half of 2022. In addition, plans are underway for the third stage. The construction of its 60,000L capacity is scheduled to commence in 2022.
While ramping up capacity progress and cementing quality management, Henlius strikes a pioneer path of adopting cutting-edge technology, such as continuous manufacturing technology, to bring down cost and streamline production process.
We have built an in-house commercial team focused on domestic market. The team is responsible for the commercialisation of our core oncology products including 汉曲优® (trastuzumab), 汉贝泰® (bevacizumab injection), Serplulimab (anti-PD-1 mAb) etc. We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 450 professionals; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide.
